Not Yet RecruitingPhase 1/2

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

86 participantsStarted 2026-03-23

Plain-language summary

To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers
✕. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
✕. Has a history of psychoactive substance abuse that cannot be discontinued
✕. Has any severe and/or uncontrolled disease.

What they're measuring

Summary of DLT events (Phase Ib)

Timeframe: At the end of Cycle 1 (each cycle is 28 days)

Overall response rate (Phase Ⅱ)

Timeframe: At the end of Cycle 3 (each cycle is 28 days)

Trial details

NCT IDNCT07493330

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-12-12

Contact for this trial

Weili Zhao

086-022-64370045 zwl_trial@163.com

View on ClinicalTrials.gov More PTCL trials